HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

James A Spudich Selected Research

Cardiac Myosins

1/2021Hypertrophic cardiomyopathy β-cardiac myosin mutation (P710R) leads to hypercontractility by disrupting super relaxed state.
1/2021Nanomechanical Phenotypes in Cardiac Myosin-Binding Protein C Mutants That Cause Hypertrophic Cardiomyopathy.
1/2020The hypertrophic cardiomyopathy mutations R403Q and R663H increase the number of myosin heads available to interact with actin.
1/2019Three perspectives on the molecular basis of hypercontractility caused by hypertrophic cardiomyopathy mutations.
1/2019β-Cardiac myosin hypertrophic cardiomyopathy mutations release sequestered heads and increase enzymatic activity.
1/2018Deciphering the super relaxed state of human β-cardiac myosin and the mode of action of mavacamten from myosin molecules to muscle fibers.
6/2017The myosin mesa and the basis of hypercontractility caused by hypertrophic cardiomyopathy mutations.
2/2017Biophysical properties of human β-cardiac myosin with converter mutations that cause hypertrophic cardiomyopathy.
12/2016Early-Onset Hypertrophic Cardiomyopathy Mutations Significantly Increase the Velocity, Force, and Actin-Activated ATPase Activity of Human β-Cardiac Myosin.
1/2016Multidimensional structure-function relationships in human β-cardiac myosin from population-scale genetic variation.
For more, sign up at right for free...

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown:


James A Spudich Research Topics

Disease

19Hypertrophic Cardiomyopathy (Hypertrophic Obstructive Cardiomyopathy)
11/2021 - 12/2009
6Cardiomyopathies (Cardiomyopathy)
01/2018 - 01/2012
5Dilated Cardiomyopathy (Cardiomyopathy, Congestive)
01/2018 - 03/2014
4Stroke (Strokes)
01/2016 - 10/2002
2Hypertrophy
01/2019 - 02/2016
2Fibrosis (Cirrhosis)
01/2019 - 02/2016
2Heart Failure
01/2016 - 05/2015
2Inborn Genetic Diseases (Disease, Hereditary)
01/2016 - 03/2014
1Heart Diseases (Heart Disease)
01/2021
1Neurologic Gait Disorders (Gait, Hemiplegic)
10/2020
1Brain Injuries (Brain Injury)
10/2020
1Dystocia
01/2019
1Cardiac Sudden Death (Sudden Cardiac Arrest)
01/2016
1Cardiomegaly (Heart Hypertrophy)
01/2016
1familial dilated cardiomyopathy
10/2015
1Sudden Death
05/2015
1Cardiac Arrhythmias (Arrythmia)
05/2015
1Familial Hypertrophic Cardiomyopathy (Cardiomyopathy, Familial Hypertrophic)
06/2012

Drug/Important Bio-Agent (IBA)

19Cardiac MyosinsIBA
01/2021 - 12/2009
11Myosins (Myosin)IBA
01/2021 - 01/2007
9Proteins (Proteins, Gene)FDA Link
11/2021 - 01/2012
3myosin-binding protein CIBA
01/2020 - 03/2014
3TropomyosinIBA
10/2017 - 01/2012
2MYK-461IBA
01/2018 - 02/2016
2Troponin T (Troponin T1)IBA
10/2017 - 01/2013
2Protein Isoforms (Isoforms)IBA
05/2015 - 06/2012
2Adenosine Triphosphatases (ATPase)IBA
03/2015 - 10/2002
1Carrier Proteins (Binding Protein)IBA
01/2021
1MethyltransferasesIBA
01/2019
1Histidine (L-Histidine)FDA Link
01/2019
1Trinitrotoluene (TNT)IBA
10/2017
1Myosin Heavy Chains (Myosin Heavy Chain)IBA
02/2016
1UtrophinIBA
05/2015
1Mutant Proteins (Protein, Mutant)IBA
03/2015
1ActomyosinIBA
01/2013
1CalciumIBA
01/2013
1Adenosine Triphosphate (ATP)IBA
11/2007
1Myosin Type I (Myosin IA)IBA
11/2007
1Myosin Type IIIBA
11/2007
1myosin VIIBA
01/2007
1Myosin Type VIBA
10/2002
1pyreneIBA
10/2002